Theralase Technologies Inc. V.TLT

FDA approves Novartis drug

[enriquesuave]

Which Novartis paid $2.1 Billion USD from Endocyte I believe about 2 years ago. Endocyte went from $50 Million MC to $2.1 Billion buy out within a year after good PH2 data if I remember. So a 42 bagger in the span of 12 months for a less appealing drug with less efficacy IMo albeit for a different indication.  How much will we go up if data is what we hope for?

https://www.medpagetoday.com/hematologyoncology/prostatecancer/97852?xid=nl_mpt_DHE_2022-03-24&eun=g1440998d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Evening%202022-03-24&utm_term=NL_Daily_DHE_dual-gmail-definition

[enriquesuave]

Also here https://www.biopharmadive.com/news/novartis-fda-approval-pluvicto-prostate-cancer-endocyte/620973/  

[Yajne]

I like those numbers enrique. Simple math suggests that TLT would be valued at over $12 with similar metrics for MC under this deal. Then there are all the other advantages that TLT's ACT offers. The Novatis purchase provides what should be a minimum baseline for valuation with considerable (multiples!!) upside from that. So, expecting something (multiples) far north of $12 for my shares. GLTA

[CatoCan]

Just need to get that FDA approval. FIngers Crossed 

[ScienceFirst]

EnriqueSuave ... Your example of market valuation is in line with the ranges I mentioned in my earlier post: 36x-70x upside based on similar BTD for BCG-unresponsive 

[Sunvalley]

Thank you ScienceFirst and EnriqueSuave for bringing us all a perspective on where we  possibly could end up if this treatment is sucessful. Mighty fine reading I must say!